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Infection of the female genital tract can result in serious morbidities and mortalities from 
reproductive disability, pelvic inflammatory disease, cancer, to impacts on the foetus such as 
infant blindness. Whilst therapeutic agents are available to cure or in some cases reduce the 
disease burden, frequent testing and treatment is required to prevent the occurrence of the 
severe disease sequelae. Hence, sexually transmitted infections remain a major public health 
burden with ongoing social and economic barriers to prevention and treatment. 
Unfortunately, whilst there are two success stories in the development of vaccines to protect 
against HPV infection of the FRT (Female Reproductive Tract), many serious infectious 
agents impacting on the female reproductive tract still have no vaccines available. 
Vaccination to prevent infection of the female reproductive tract is an inherently difficult 
target, with many impacting factors such as; appropriate vaccination strategys/mechanisms to 
induce a suitable protective response locally in the genital tract, variation in the local immune 
responses due to the hormonal cycle, selection of  vaccine antigen(s) that confers effective 
protection against multiple variants of a single pathogen (e.g. the different serovars of C. 
trachomatis), and timing of the vaccine administration prior to infection exposure. In spite of 
these difficulties there are numerous ongoing efforts to develop effective vaccines against 
these infectious agents and it is likely this important human health field will see further major 
developments in the next 5 years.  
  
 Infection of the female reproductive tract result represents a serious health 
burden worldwide  
Infections of the female reproductive tract that are associated with high morbidities and 
mortalities around the world include; human immunodeficiency virus (HIV), human 
papillomavirus (HPV), Herpes Simplex Virus (HSV), Hepatitis B (HepB), Chlamydia (C.) 
trachomatis, Neisseria (N.) gonococcus, Treponema (T.) pallidum (syphilis), group B 
streptococcus during pregnancy, and Trichomanas (T.) vaginalis. Female reproductive tract 
infections (RTIs) usually originate in the lower genital tract as vaginitis and cervicitis and 
may produce symptoms such as abnormal vaginal discharge, genital pain, itching, and a 
burning feeling with urination. However, for some infections such as Chlamydia, a high 
prevalence of asymptomatic infection occurs, which is a barrier to effective control. RTIs 
impose a heavy toll on women, if untreated can cause the serious consequences of pelvic 
inflammatory disease, chronic pelvic pain, infertility, ectopic pregnancy, cervical cancer, 
menstrual disturbances, pregnancy wastage, low birth weight babies, and increased risk of 
HIV infection and transmission. A number of these infections can be effectively treated once 
diagnosed, however, the greatest burden of these treatable infections is in developing 
countries where access to treatment is limited (Fig 1). The WHO estimates that in 1999 alone 
116.5 million curable sexually transmitted infections (STIs) occurred, however, the majority 
of these were in locations where access to health care is severely limited (e.g. 32 million in 
sub-saharan Africa). In developing countries reproductive tract infections rank second to 
maternal morbidity and mortality as a health encumbrance for women [1]. In the near future, 
the most pressing health impact of these infections is likely to be their role in increasing the 
infection and transmission rates of the HIV virus [2]. 
The leading bacterial agents with known established pathological impacts on the FRT (N. 
gonorrehoeae, C. trachomatis, T. palladium, Haemophilus ducreyi) currently cause a 
combined total of greater than 169 million infections annually in humans [3]. Importantly, it 
seems that in both developing and developed countries the actual incidence of infections are 
likely to far exceed those which are diagnosed and treated [4-5]. The antibiotics typically 
used to treat these bacterial FRT infections include; ceftraxone, ceftriaxone, ciprofloxacin, 
ofloxacin, all of which are listed on the WHO essential medicines scheme for developing 
countries at a cost of 0.019-0.32 USD (US $) per dose. However, azithromycin, the most 
effective treatment for Chlamydia is not currently listed on the WHO essential medicines 
scheme. These medicines all retain the same relative cost effectiveness in developed 
countries, costing from approximately $4.80 per dose to $11.50 for a dose of Azithromycin 
[6]. Even though affordable antibiotic treatment is available for these infections; limited 
access to testing and treatment, or infrequent testing and treatment, or treatment after 
pathologies have already developed are major factors in the spread and health burden of these 
infections. Well implemented and robust vaccination programs have the potential to deliver 
longer term protection against infection and also prevention of the resultant morbidities. Thus 
vaccine strategies are likely to deliver a far greater cost:benefit once they can be successfully 
implemented.   
 
There is also a pressing need for vaccines to target viral STIs from both a population health 
and economic perspective, but unfortunately the outcomes of recent clinical trials of 
experimental HIV vaccines have not been encouraging. The infection and disease morbidity 
rates are far greater for the viral infectious agents compared to bacterial STIs. Worldwide 
there are; greater than 33 million HIV positive individuals, HSV2 prevalence maybe as high 
as 20%, 350 million cases of chronic hepatitis cases occur annually, and there are at least 500 
000 cases of cervical cancer annually. There are no treatments to cure any of these infections. 
The treatments which exist to reduce the disease burdens require established health 
infrastructure and high socioeconomic circumstances. Current HIV antiretroviral treatments, 
are costly, involve complicated combination therapy regimens, and can result in the 
development of viral resistance in some cases (reviewed in [7]). The current treatments for 
HSV are acyclovir, valacyclovir, and penciclovir, which effectively prevent 70-80% of the 
symptomatic recurrent epiosodes. However, these require multiple doses for up to 10 days at 
a cost of 65-100 USD to treat a primary infection [8]. HepB treatments include; interferon 
alfa,  pegylated  interferon  alfa‐2a,  lamivudine,  and  adefovir to reduce the liver 
inflammation and further progression of the chronic disease [9]. Antiviral drug treatment is 
not recommended for HPV (CDC guidelines, USA), instead participation in cervical cancer 
screening programs and intervention when pathological lesions are detected is the 
recommended HPV strategy. Thus, the development of vaccines to prevent viral FRT 
infection and disease morbidities is imperative to reduce the health burden from these 
infections. The recent success of vaccines against HPV (Gardasil® and Cervarix®) reinforces 
the value of vaccination as a means of targeting these infections and associated disease.   
 The most common protozoan organism that causes disease in the FRT is Trichomonas. There 
are an estimated 170 million cases worldwide annually. The infection can result in 
symptomatic reproductive tract infection, pelvic inflammatory disease, and has been 
associated but not casually linked with adverse pregnancy and reproductive capability 
outcomes in women [10]. The infection is also associated with increased risk of HIV 
infection [11]. Trichomoniasis is curable with treatments such as metronidazole or tinidazole. 
The potential for development of a vaccine may be limited due to evidence that repeat 
infections do not result in protective immunity in humans [12]. 
 
Given that the treatments available for all STIs require early diagnosis, usually require 
ongoing or multiple dosing, do not actually clear the infection in the case of viral STIs and 
may not be administered in time to reduce the reproductive tract morbidities it is clear that 
vaccines should be the major focus of efforts to combat these diseases. Indeed, globally 
vaccines are acknowledged as the most effective health intervention strategy, with the 
childhood vaccine programs having saved approximately 20 million lives in the past two 
decades [13]. We review here the issues and strategies involved in developing vaccines to 
prevent infection of the female reproductive tract, highlight the key successes in the field, and 
present a perspective on where the next successes may arise. 
 
 
Fig 1. Global prevalence of curable STIs in adults around the world in 1999. This figure 
has been reproduced using data sourced from the WHO website. 
 
The Female Reproductive Tract 
The female reproductive tract is a unique immune compartment in the body. The tissue 
structure is continually changing, and the hormonal cycle also alters the immune profile of 
this tissue. Bacterial flora have a critical role in preventing infection in the lower genital tract, 
whilst limiting damaging ascending infection and facilitating effective conception and 
reproduction are features of the upper genital tract. Thus, this mucosal location has quite 
distinct immunological and hormonal factors that can impact dramatically on the design of 
vaccines to target STIs.  
Hormonal regulation of FRT  
The changes induced in the immunology of the female reproductive tract by fluctuating 
hormone levels may present a challenge for the development and delivery of successful 
vaccines. Progestins and estrogens are the principle hormones acting on the female 
reproductive tract (FRT). Hormone levels fluctuate naturally during the menstrual cycle but 
are also influenced by the use of hormonal contraceptives, hormone replacement therapies, 
pregnancy and chronic stress. These changes in hormone levels cause alterations to immune 
cell number and function and have the potential to profoundly influence the immunity of the 
host and the efficacy of any vaccination. 
Innate immunity provides the first level of pathogen recognition and defence. The mucosal 
surfaces of the body including the female reproductive tract frequently encounter and respond 
to pathogenic attack. Innate immune mechanisms at the mucosal surface include the 
thickening of the epithelial cell layer and the production of mucins by epithelial cells, and 
production of antimicrobial products such as secretory leucocyte protease inhibitor (SLPI), 
cathelicidins and defensins by epithelial cells. It has been reported that -defensins can 
directly defend against microbes whereas -defensins act by allowing immune cells to access 
vascularised tissues [14]. SLPI is produced by macrophages as well as epithelial cells and is 
known to have bactericidal effects [15]. The sex hormones present in the reproductive tract 
regulate the production of these innate immune factors that represent the first line of defence.  
Detection of foreign microbes occurs through the sensing of conserved pathogen associated 
molecular patterns (PAMPs) expressed by pathogens. These PAMPs are recognised by 
families of receptors such as the Toll like receptors (TLRs) and NOD/CARD receptors 
present on immune cells and also epithelial cells. Recognition of pathogens such as bacteria 
and viruses via these receptors signals the immune system to mount a strong response against 
the foreign pathogen to clear infection. The immune amplifying properties of many adjuvants 
are based on successful activation of TLRs to stimulate a strong immune response against the 
vaccine antigen. TLRs are sensitive to the presence of sex hormones and their expression is 
differentially regulated during the menstrual cycle. Expression of TLRs is reported to be 
much higher in human endometrial tissue during the progesterone high secretory phase of the 
menstrual cycle compared to other times [16-17]. 
 
Changes in the cellularity of the FRT are detectable at different times during the menstrual 
cycle when the body is under the influence of different sex hormones. Levels of antibody 
secreting B cells, NK cells, T cells, macrophages and DC’s are reported to be affected by the 
presence of sex hormones. NK cells are reported to decrease in frequency in the presence of 
estradiol [18-20]. Macrophages and dendritic cell (DC) populations in the FRT are reported 
to vary relative to the levels of ovarian hormones present, with frequencies of macrophages 
and immature DCs highest at the menstrual phase of the cycle [21-22]. The cytolytic activity 
of CD3 T cells in the human uterine endometrium is influenced by the menstrual cycle with 
activity detectable during the proliferative, but not the secretory phase [23]. Lymphoid 
aggregates have been reported in the human uterine endometrium and are linked to the 
menstrual cycle. These lymphoid aggregates consist of a core of B cells surrounded by CD8 
T cells and an outer halo of monocytes and macrophages [24-25]. The observed aggregates 
were of small size during the proliferative period and were observed to greatly increase in 
size during the secretory phase, but were absent in post-menopausal women [25]. 
Fluctuations in the number of antibody secreting B cells in relation to ovarian hormones has 
been reported in healthy women, with the highest frequency of cells present during the peri-
ovulatory stage of the menstrual cycle [26]. It has also been shown in rats that the levels of 
IgA and IgG in cervicovaginal secretions are under the regulation of sex hormones, with both 
estradiol and progesterone treatment lowering measured antibody titres [27]. 
 
Fluctuations in the levels of sex hormones in the reproductive tract also affects the process of 
antigen presentation, a critical step in the initiation of a successful immune response. Both 
professional antigen presenting cells (APCs; Dendritic cells (DCs) and macrophages) and 
also non-conventional APCs (stromal and epithelial cells) are influenced by the presence of 
sex hormones. Estrogen, or other ER ligands can directly activate DCs, which express 
estrogen receptors [28-29], indirectly regulating adaptive immune responses through affects 
on DC function. In vitro, estrogen pre-treatment of human monocyte derived DCs has been 
shown to cause increased ability to stimulate naïve CD4 T cell responses [30]. Human 
macrophages have also been shown to express a variant estrogen receptor – meaning estrogen 
can have direct effects on this cell type also [31]. The presence of progesterone can 
effectively induce semi-mature tolerogenic DCs and reportedly inhibits mature DC activity – 
inhibiting the development of an immune response [32].  
Collectively, the hormone-induced changes in many aspects of the innate and adaptive 
immune response can also affect susceptibility to infection by sexually transmitted pathogens. 
For example, women are less susceptible to chlamydial infection during the progesterone 
dominant secretory phase of the menstrual cycle and we have demonstrated that this is due to 
activation of multiple innate immune pathways in progesterone-treated endocervical cell lines 
and secretory phase primary endocervical cells (Wan et al., submitted, personal 
communication). Furthermore, Wira and Fahey [33] have identified a window of 
vulnerability to HIV infection during the normal menstrual cycle. During this period (7-10 
days following ovulation) multiple components of the innate, humoral and cell-mediated 
immune response are suppressed by sex hormones to optimize conditions for procreation, the 
side affect of which is deceased anti-viral immunity and increased susceptibility to infection. 
 
 
Hormonal variation can also impact on the efficacy of vaccination, depending on the route of 
administration. Studies in mice found that nasal vaccine administration could induce 
neutralizing titres of HPV16 IgG and IgA throughout the estrus cycle, whereas parenteral 
immunisation could only achieve neutralising antibody titres when administered during 
diestrus [34]. Human studies have shown that vaginal vaccination elicits variable antibody 
responses, depending on the timing of vaccination within the menstrual cycle, with 
administration on days 10 and 24 of the menstrual cycle eliciting better protection and higher 
antibody titres than patients vaccinated independently of the timing of the menstrual cycle 
[35]. Nasal vaccination has been shown to be superior to rectal or vaginal immunisation in 
the production of cholera toxin B (CTB) specific antibodies after vaccination with CTB, 
irrespective of the influence of the menstrual cycle [36]. Interestingly, although nasal delivery 
has proven to be efficient at inducing systemic and mucosal neutralising antibody to prevent 
HPV infection a recent murine study using an HPV associated tumor model has suggested 
that in animals with existing disease where cell mediated immunity is required, parenteral 
immunisation may be a more effective delivery method [37]. The recently approved and 
widely administered vaccines for HPV, Gardasil® and Cervarix®, are administered 
intramuscularly, independent of the stage of cycle and the observed protection correlates with 
circulating levels of IgG [38].  
 
Successful vaccines which protect against infection of the female genital 
tract 
Vaccines are one of the most effective public health and economic advances in medicine. The 
eradication of smallpox, for example, cost approximately 25 million USD during the 
campaign, but has since saved approximately 40 million lives, and 275 million USD annually 
in quarantine and treatment costs [39]. Yet, the vaccine market currently represents only 2% 
of the worldwide pharmaceutical market [40]. Vaccination to protect against infection and 
disease in the female reproductive tract represents a key area of innovation and advance for 
the vaccine field. The successful development and implementation of the HPV vaccine and 
the HepB vaccine demonstrate that vaccines can be an effective intervention for female 
reproductive tract health. Vaccination to protect women (and men) against sexually 
transmitted disease (STD) has incredible potential to save lives, reduce morbidity, decrease 
global STD expenditures, reduce the spread of HIV/AIDS and contribute to improved 
reproductive health [41]. 
 
Vaccination to prevent infection and cervical cancer: Human Papillomavirus  
HPV is the etiological agent for cervical cancer [42]. Cervical cancer is second most common 
cause of cancer-related deaths in females worldwide. HPV are non-enveloped dsDNA viruses 
which infect the squamous epithelia. The persistent infection of these squamous epithelia is 
associated with cervical cancer. Once the infection becomes persistent, the transcription of 
two viral oncogenes (E6 and E7) is activated. These proteins inactivate the host cell tumor 
suppressors p53 and retinoblastoma gene, which ultimately leads to the cervical 
intraepithelial neoplasia which is the first stage of cervical cancer [43]. The two vaccines 
clinically in use both prevent the initial infection with HPV (Gardasil®, Merck and 
Cervarix®, GlaxoSmithKline). Gardasil® has already been demonstrated to protect against 
neoplasia and induce an immune response detectable for at least 5 years [44-45]. The 
vaccines are both virus like particle formulations with the viral L1 surface protein. Gardasil® 
contains 4 L1 protein variants to protect against HPV genotypes 6, 11, 16 and 18. This 
coverage of the genotypes protects against 70% of the cervical cancers and 90% of female 
genital infections. Cervarix® is formulated with two of the L1 protein variants; HPV16 and 
HPV18. The vaccines have now been approved for use in many countries worldwide, 
however the impact of the vaccination program will take a number of decades to be apparent 
as the infection and development of cancer is predicted to have as much as a 20 year delay. 
Recent studies have however provided promising data on the effectiveness of the Gardasil® 
vaccine. In Victoria Australia there has been a significant decrease in high-grade cervical 
abnormalities in women aged less than 18 years in the 3 years since the vaccine was 
introduced [46]. These data suggest that wide-spread introduction of the HPV vaccine in 
girls, prior to the onset of sexual activity, has the potential to greatly reduce the incidence of 
cervical cancer. Inclusion of more HPV genotypes in second-generation vaccines should 
further enhance protection and a vaccine targeting 9 different strains of HPV (MERCK) is 
currently in Phase II clinical trials. The introduction of the HPV vaccine has demonstrated a 
number of key advances for this vaccination field; firstly that protection against a major 
female genital tract infection is possible by vaccination, that the public health and regulatory 
agencies in several countries have allowed a vaccine program against a major STI to be 
implemented in teenage girls.  Extending vaccination to include males may further reduce the 
incidence of cervical cancer as well as reducing the incidence of HPV-induced genital lesions 
in males [47-48]. 
 
Reduction of chronic liver disease: Hepatitis B vaccine  
Hepatitis B (HepB) is a blood borne and sexually transmitted virus that causes acute and 
chronic hepatitis. Virus is readily detected in semen and vaginal fluids of infected individuals 
and it is believed that most adults, who are not intravenous drug users, acquire infection 
through sexual contact [49]. There are estimated to be approximately 2-billion infected 
individuals world-wide, however the major burden of this disease arises from the chronic 
liver inflammation. There are 8 serologically distinct genotypes which are all protected 
against by the available vaccines. The hepatitis B vaccine has been in use since the early 
1980s, with high risk groups initially targeted for immunisation. It is only in recent years that 
more universal vaccination programs have been implemented with Australia introducing a 
universal infant vaccination strategy in 2000. The vaccine is based on the viral surface 
antigen (envelope protein) and contains an aluminium hydroxide adjuvant (Alum). In infants 
the HepB vaccine is now commonly administered as part of a multi-component vaccine 
targeting a number of pathogens. One example is the GlaxoSmithKline Infanrix® vaccine 
(diphtheria, tetanus, acellular pertussis, poliomyelitis, and Heamophilus influenzae type B). 
The 98% decline in rates of hepatitis infection in children under 13 and 76% decline in 
infection rates in adults over the 15 years since the vaccine was introduced widely in the USA 
demonstrates the major public health benefits of an effective and well implemented vaccine 
program [50-51]. Similar successes have been reported in both rural and urban settings from 
developed and developing countries worldwide. The vaccine is effective in the majority of 
the population but requires a booster dose in adults which has some issues for compliance in 
some settings.  
 
Vaccines in the pipeline 
Vaccines to prevent against reproductive tract infection have not yet been successfully 
developed for HIV, Chlamydia, gonococcus, HSV and many of other pathogens. There are a 
number of reasons for these problems. These issues include; the complex life cycles of the 
organisms, considerable diversity of the sequence of the surface protein antigens, lack of 
complete understanding of immunological mechanisms of control and protection against the 
disease, lack of safe, approved adjuvants that will drive vaccine-induced humoral (Th2) 
and/or cellular (Th1) mucosal immune response and failure to induce longer term immunity.  
Furthermore, vaccine trials have been hampered by the limited tools, or efforts, to measure 
protective mucosal immunity within the female reproductive tract. In many cases the 
demonstration of antibody and cell-mediated responses in peripheral blood following 
vaccination has not resulted in protection against infection within the FRT. Furthermore, the 
infectious agents which commonly infect the FRT are long evolved human pathogens and 
many have developed multiple mechanisms to evade host immune defences, such that in the 
case of N. gonorrhoeae even natural infection fails to elicit protective immunity and 
individuals can be re-infected multiple times [52] while the multiple serovars of C. 
trachomatis mean that infection induces only short-lived, serovar-specific immunity  [53].  
HIV vaccines 
Development of a HIV vaccine is one of the most pressing public health priorities worldwide. 
Currently 35.5 million people worldwide are infected with HIV and approximately 30 million 
are estimated to have died from AIDS related causes [54]. Unfortunately whilst there are 
numerous vaccine trials underway and previously attempted there has not yet been an 
effective vaccine developed for HIV. There are several comprehensive reviews specific to 
HIV vaccine development; hence we will not explore this area further in this review [55-56]. 
Herpes simplex virus 2 vaccines  
HSV2 infection is the causative agent for genital herpes, with 20% of adults infected in the 
USA [57].  The infection is contracted through the skin or mucosal surfaces and establishes 
within the sensory neurons as a life-long latent infection. The latent virus can be reactivated 
by physical or emotional stress, fatigue, genital irritation or trauma and can either be 
asymptomatically shed or form painful, fluid-filled blisters/ulcers on the genitalia and 
surrounding tissues  Neonatal transmission results in serious consequences with high 
incidences of morbidity and mortality. Th1 immunity with a predominance of IFN- has been 
demonstrated to be required in the human immune response to achieve protective immunity 
[58], and for this reason vaccine methodologies have focussed on inducing a Th1 response.  
There have been numerous trials of HSV vaccines. Subunit vaccines based on the surface 
glycoproteins have been extensively tested. The trials all induced both antibody and T cell 
proliferation in phase I trials but no significant protection against infection in phase II has 
been demonstrated. The potential effectiveness of a vaccine which doesn’t prevent infection 
but reduces clinical presentation has been acknowledged as a more realistic goal for HSV2 
vaccination [59]. There have been two separate phase III trials which reduced clinical 
symptoms (70% efficacy), interestingly this effect was only observed in HSV1 and HSV2 
seronegative females [60-61]. Thus, prior infection and gender are factors which influence 
the efficacy of HSV2 subunit vaccines tested to date. A number of different killed and DNA 
vaccines have been tested for HSV, in either animal models or human clinical trials, with 
little success (reviewed [59]). A novel live attenuated vaccine (GlaxoSmithKline) did not 
protect against recurrence of activation of the latent virus or shedding in a phase II trial with 
HSV2 seropositive women [62]. The vaccine did induce a strong cytotoxic immune response 
and thus has potential as a prophylactic vaccine. A phase II clinical trial is currently 
underway with a different live attenuated strain (AuRix), and a replication impaired live 
attenuated vaccine is in pre-clinical development by Avant Immunotherapeutics. Depending 
on the outcomes of these trials, a live attenuated vaccine which prevents the HSV2 symptoms 
may be one of the next FRT vaccines to progress to clinical use. 
 
Chlamydia vaccines  
Chlamydia trachomatis infection is the most common sexually transmitted bacterial disease 
worldwide, with over 91 million cases estimated annually (WHO). Despite the availability of 
a sensitive diagnostic test and also effective antibiotics, the incidence of C. trachomatis 
infections continues to increase [63]. One reason for this is the fact that in many cases, C. 
trachomatis genital infections are asymptomatic; 70-90% in females and 30-50% in males.  
The long-term sequaele of untreated C. trachomatis infections can be serious.  In women, 
chronic infection can lead to scarring of the reproductive tract which can subsequently lead to 
salpingitis, ectopic pregnancy, pelvic inflammatory disease and infertility. In men, infection 
can lead to inflammation which can result in prostatitis, epididymitis and orchitis [64]. All 
these factors lead to the urgent need for an effective vaccine to treat C.trachomatis genital 
tract infections. 
Early vaccine studies used whole inactivated Chlamydia but these led to enhanced 
immunopathology in some of the vaccinees [65-66] and as a consequence, this has led 
researchers to take a more cautious and rational approach to develop safe and effective 
chlamydial vaccines. Mouse studies suggest that both mucosal IgA as well as Th1 CD4+ T 
cells play a crucial role in controlling chlamydial infections [67]. Mucosal antibodies can be 
neutralising and therefore play a role in limiting chlamydial urogenital tract infection [68] but 
the role of IgA in protective immunity is probably less crucial [69]. By comparison, 
interferon-gamma producing T cells are considered to be the major effector cells in 
controlling new chlamydial infections. For example, in the mouse model, mice deficient in 
interferon-gamma receptor but competent in mucosal IgA production fail to clear a primary 
chlamydial genital tract infection [70]. 
Recent vaccine studies are starting to show some promise although most work is still being 
conducted in the Chlamydia muridarum – mouse infection model. Other animal models for 
chlamydial genital infection, and hence vaccine development, include the guinea pig and non-
human primates [71] but very few studies have yet been conducted in these non-mouse 
models. A key question for the development of an effective vaccine is the choice of antigen. 
Most work to date has focussed on the chlamydial major outer membrane protein, MOMP. 
While MOMP has both strong B and T cell epitopes and therefore can provide reasonable 
protection against live challenge, it shows considerable variability between serovars. This has 
led recently to an increase in attempts to identify new vaccine candidates using a range of 
approaches [72] including, (a) 2D gel electrophoresis and immunoblotting [73-74] to identify 
chlamydial antigens recognised by human antibodies.  MOMP antibodies tend to dominate in 
these assays however. (b) Radio-immunoprecipitation combined with 2D gel electrophoresis. 
Indeed, this approach confirmed the importance of the Chlamydia-secreted protease factor 
(CPAF) [75] which is currently a strong vaccine candidate. (c) Genome-wide protein 
expression for detecting both antibody and T cell responses [76]. Chlamydia’s small genome 
makes this approach more feasible and it has led to a new set of potential vaccine antigens. 
(d) Antigen discovery using T cell lines. This technique has been successfully used to 
generate T cell lines that were protective in a systemic murine infection model [77]. (e) 
Immunoproteomics [78] has recently been used by Brunham and colleagues to examine the 
sequence of peptides presented via MHC class II on antigen presenting cells.  This approach 
identified a range of antigens, including several Pmps. Together, these approaches have 
added a large number of new potential candidates (such as CPAF, PmpD, PmpG, CopN, 
IncA, NrdB, Pgp3) to the early targets of MOMP, Omp2 and heat shock protein 60. It is 
likely that an effective chlamydial vaccine will require a cocktail of antigens to be 
sufficiently effective.  The other critical area for an effective vaccine is the method of 
delivery and the use of adjuvants. A range of delivery systems have been evaluated, 
including, immunostimulating complexes [79], detergent/surfactant-based adjuvants [80], live 
viral vectors [81], Vibrio cholerae ghosts [82], liposomes [83] and cytokines. However, there 
is still the need for more work on adjuvants that stimulate the required T cell response and 
importantly, induce homing of the effector cells to the site of the natural infection; i.e. the 
genital tract. 
Because of the difficulties in demonstrating reasonable protection against live challenge in 
addition to safety, human clinical trials for a chlamydial STD vaccine are still progressing 
very slowly. An important aspect that is often not considered is the dynamics of vaccination 
strategies.  Gray et al. (2009) [84] used a mathematical modelling approach to show that 
targeting 100% of one sex (eg. females) is likely to have a greater epidemiological impact 
than administering the vaccine to 50% of both sexes. They suggested that an effective 
vaccine could have a significant impact if it could significantly reduce the infectious burden 
in an individual to a level that made transmission less likely, without necessarily having to be 
completely sterilising. On a promising note, they suggested that a fully protective vaccine 
(the holy grail of chlamydial vaccine research) could potentially eradicate Chlamydia 
infection within 20 years. 
 
Gonococcus 
N. gonorrhoeae sexually transmitted infection can be asymptomatic in both women and men; 
however the infection is associated with the development of chronic pelvic pain, PID, tubal 
factor infertility and ectopic pregnancy. There are approximately 300,000 reported 
gonococcus cases annually in the USA, with the actual incidence predicted to be double this 
number [85].  Gonococcus vaccine develop has been severely hindered by several factors; (1) 
the considerable antigenic variability of the surface antigens, (2) the fact that natural 
infections do not induce a strong humoral or cytotoxic immune response, although natural 
infections do eventually resolve (reviewed, [86-87]). This may be due to the innate 
inflammatory response and it appears that long-term protection against re-infection does not 
occur [88]. (3) Finally an effective animal model has only recently been developed. In spite 
of this, there have been vaccine trials using the subunit vaccines based on the gonococcus 
pilin or porin. A subunit vaccine trial using pilus did induce a local antibody response, 
however it failed to protect against subsequent infections [89]. Porin and other outer 
membrane proteins have also been considered and tested as potential vaccine antigens; 
however there are no published reports of any of these progressing clinical trials (see Zhu et 
al., for a more comprehensive review of this topic [86]).  
 
Vaccination to protect pregnant women against reproductive tract 
infections: benefits and risks 
Reproductive tract infections can result in significant additional impacts in pregnant women; 
hence we will separately review these considerations here. The medical, social, and legal, 
risks of immunizing pregnant women against infectious agents for their protection as well as 
their infant’s protection are important issues. Emphasis has been placed on maternal 
immunisation primarily for protecting newborns and infants. There are several groups of 
infectious organisms that have potential for affecting the pregnant woman, her foetus, or 
neonate. 
i) Placental infection resulting in congenital diseases: Toxoplasmosis, cytomegalovirus, 
HSV,   rubella, syphilis, HIV, parovirus B-19, HepB, malaria, and varicella [90-94].  
ii) Infections in neonates:  Hemophilus (H.) influenzae type B, Streptococcus (S.) 
pneumonia, Group B Streptococcus (GBS), Staphylococcus (S.) aureus [95-96].  
iii) Preterm birth: Mycoplasma (M.) hominis, Ureaplasma (U.) urealyticum, Clostridium, 
Leptospira, Trichomonas (T.) vaginalis, bacterial vaginosis, and bacteroides [97-100]. 
During pregnancy, the maternal immune system must accept/tolerate the implantation and growth 
of a semi-allogeneic fetus. As a result of this, changes occur in the maternal immune system 
during pregnancy. These include a general suppression of Th1 immunity and an increase in Th2 
immunity. In addition, there is an influx of Treg cells into the uterus during the first and second 
trimesters of pregnancy, cells that maintain tolerance to the paternal antigens on developing 
fetus, and expression of a number of molecules such as IDO and non-classical and MHC 
molecules (HLA-G, HLA-E) that suppress activation of maternal T cells and NK cells 
respectively (reviewed [101]). Thus, while the administration of live-attenuated vaccines aimed 
at developing Th1/CMI responses is not recommended during pregnancy, the pregnant immune 
system still retains the capacity to respond to killed or inactivated vaccines to produce humoral 
responses that are equivalent to those in non-pregnant women [102-103].  
 
The potential benefits of immunizing pregnant women   
Immunisation programmes in pregnancy are among the most cost beneficial health 
interventions. They can significantly reduce the occurrence of preventable disease thereby 
benefitting the pregnant women and infant [104]. Preparations of new vaccines are also required 
against infectious agents that are known to result in reproductive pathology and congenital 
malformation if the infection of the mother occurs during pregnancy. Active campaigns to 
vaccinate the pregnant women should have the following public health benefits: 
i) Eliminating teratogenic and embryopathic congenital infections of the embryo and 
placenta: i.e. HSV, varicella, CMV, toxoplasmosis, rubella, syphilis, HIV, 
parovirus B-19, HepB, and malaria [105-107].  
ii) Eliminating neonatal infections acquired during perinatal period via maternal 
transplacental antibodies for which the neonate has not developed antibodies: i.e. 
GBS, H. influenzae type B, S. pneumoniae [105-106]. 
iii) Elimination of intrauterine infections that may contribute to premature birth: i.e. 
Bacteroides, M. hominis, U. urealyticum, Clostridium, Leptospira, T. vaginalis 
(bacterial vaginosis) [108-110].  
 
The risks of immunizing pregnant women 
The perceived risks of immunizing pregnant women have resulted in a lack of data to support 
the actual risks to the women. This is paradoxical given that pregnant women are frequently 
at higher risk of serious sequelae due to infections.  
i) In general live and attenuated vaccines are contraindicated during pregnancy as there is 
primarily a theoretical risk to the foetus. The quadrivalant HPV vaccine for prevention of 
infection by HPV strains (Gardasil®) is not recommended for use during pregnancy 
[111]. 
ii) Transmission of attenuated virus to the placenta or foetus: There is a risk of live vaccine 
immunisations during pregnancy resulting in infection of the baby as sub-clinical 
infections have been documented [112-114]. 
iii) The risk that the vaccine would result in reproductive effects, congenital        
malformations, abortion, growth retardation, stillbirth, and an array of neurological 
effects [115-116]. 
iv) There have been reports of the ineffectiveness of vaccine for pregnant females, 
specifically the pneumococcus vaccine [117]. 
However, in spite of these risks several vaccines have been reported to have been 
administered to pregnant women with no increase in congenital defects for the foetus and no 
reported adverse outcomes for the mother; including Rubella (Menavix II), MMR (measles, 
mumps, rubella MMRII) (reviewed, [103]). 
 
In summary, There is considerable need for studies that include pregnant animals during 
vaccine development (pre-clinical vaccine studies) and also the inclusion of pregnant women 
in human clinical trials of new vaccines, given the lack of understanding and evidence 
relating to the impacts of vaccines on pregnant women, the altered immune status during 
pregnancy, and the potential impact of the vaccine on the mother, foetus or neonate. In 
addition, more clinical emphasis needs to be placed on vaccinations for women who are 
intending to get pregnant prior to conception. Furthermore, recognition by vaccine 
development companies that it is critical to test vaccines in pregnant women, in fact 
participation of pregnant women in vaccine trials has been permitted since 1994 (Institute of 
Medicine, USA) [103]. Whilst there may be additional risks in the inclusion of this cohort, 
the benefits of identifying successful vaccines for this cohort to reduce incidence of these 
serious infections may well far outweigh the risks [102]. While it is likely that immune 
responses to vaccines delivered during pregnancy will likely be different, given the altered 
immune status [101,118], it is also clear that the pregnant immune system retains the ability 
to respond to vaccination and produce protective immune responses [119]. Finally, it is clear 
that regardless of the results of clinical trials in pregnant women, clinical confounders may 
still exist and thus it is still critical that at the clinic a risk: benefit analysis is discussed and 
considered for each individual on a case by case basis.  
 
Adjuvants are critical for successful vaccine development 
The role of adjuvants in vaccine delivery is to improve the immunogenicity of the vaccine 
antigen(s), particularly subunit vaccines, and direct the type of adaptive response generated 
by the vaccination. As adjuvants are responsible for initiating and influencing the type of 
immune response generated by the vaccination, adjuvant choice is an important consideration 
when designing a vaccine. Although many varied adjuvants are used in animal models, few 
are approved for human use.  
The classical aluminium salts or alum adjuvant have been in use for almost one hundred 
years. It was first used in vaccination as early as 1926 to boost the immunogenicity of the 
diptheria toxoid vaccine.  Early vaccines were often fixed or heat killed pathogens, 
containing LPS and other potent immune stimulators. While these early vaccines usually 
elicited potent immune responses these were often accompanied by adverse side effects. For 
this reason, current trends in vaccine development involve the use of purified subunit 
antigens to avoid adverse reactions, however these are usually less effective at stimulating the 
innate immune response at a level sufficient to initiate a significant adaptive immune 
response. To overcome this problem stronger adjuvants are required to stimulate a strong 
innate immune response that is required to induce a long lasting and specific protective 
immune response.  Mucosal immunisation offers an extra level of challenge for good 
adjuvant design as the default immune response to mucosal delivery is often tolerance and at 
least with oral delivery both adjuvant and antigen must survive the gastric pH and digestive 
processes.  
Approval of adjuvants other than Alum for human use did not occur until the late 1990’s. 
MF59, an oil-in-water emulsion adjuvant, is composed of small droplets of the natural oil 
squalene  [120]. MF59 is appropriate for use with soluble and hydrophobic proteins as well as 
particulate antigens. Virosomes are also small and made up of a phospholipid bilayer 
containing 70% phosphotidylcholine and 20% synthetic phosphoethanolamine.  
Hemagglutinin (HA) and neuroaminidase (NA) are intercalated into the phospholipid bilayer 
and appear to enhance uptake of the virosome and associated vaccine [121]. Virosomal 
vaccination has been successfully tested in humans as an influenza vaccine without adverse 
affects [122]. There are many stronger adjuvants that are commonly used in animal models 
such as cholera toxin (CT) and its subunits and derivatives, CpGs, various cytokines such as 
IL-12, GM-CSF and complement factors. Immune stimulating complexes (ISCOMs) and 
bacterial products such as monophosphoryl lipid A (MPL) have undergone extensive testing 
and are closer to becoming a reality for use in human vaccines. New adjuvants are emerging 
for clinical use in human vaccines. Montanide, a water-in-oil emulsion and CpG, a TLR9 
agonist are undergoing clinical trials and show promise [123-124]. 
Adjuvants influence the polarity of the immune response against the vaccine antigen. The 
polarity of the ensuing immune response and subsequent memory developed against the 
vaccine antigen are important in mediating protection. Many of the currently licensed 
adjuvants, including Alum (the most commonly used) and MF59, direct the immune response 
towards a Th2 polarity [125-126]. Many bacterial and viral diseases require a Th1 cell 
mediated immune response for pathogen control and clearance, so more adjuvants that can 
act in this fashion are needed. Mucosal routes of administration show promise for the 
induction of protective immune responses, however the natural default of mucosal immune 
responses towards tolerance needs to be overcome through the use of a strong, yet safe and 
appropriately polarising, adjuvants. Our continuing advances in the understanding of innate 
immunity through the use of animal models have led to the discovery of many novel innate 
immune stimulators, which are now being trialled in animal studies and human clinical trials 
as potential adjuvants for human use.  
 
Novel and emerging methods  
Multivalent vaccines against multiple organisms are not a new innovation; however, an 
exciting advance within the field has been to use successful vaccines in combination with 
antigens from other infectious agents to elicit immunity against both pathogens. There are 
two examples of attempts to use the HPV virus like particle vaccine strategy to improve the 
immune response to antigens from other pathogens; fusion of chlamydial MOMP to the HPV 
vaccine [127], and fusion of the HSV2 protein to the HPV vaccine [128]. Additionally Vibrio 
cholera ghosts in combination with Chlamydia subunit vaccine antigens have been tested in 
animal models, as a means of harnessing the adjuvant properties of the cholera toxin [129-
130]. This approach to ‘piggy back’ on approved successful vaccines could represent a fast 
and effective step forward for the field and we look forward to the outcomes from these and 
similar studies.  
 The abundance of genome sequencing data is going to positively impact on the vaccine field, 
in fact genome mining approaches have already been used successfully in the detection of 
vaccine antigens for Neisseria meningitidis [131].  This has also enabled in silico approaches 
to identify vaccine antigens, such as a recent study from our own team, which identified 




Expert Commentary and five year view 
Sexually transmitted infections are responsible for serious morbidities and mortalities and 
pose a major burden on healthcare systems. The sequelae of STIs disproportionately impact 
on women. Treatments are available for some infections but these are often expensive, 
require active testing programs and have not been able to halt the increase in rates of 
infection. Vaccination has the greatest potential to impact on rates of infection however there 
are major obstacles to the development of vaccines for STIs. These include; understanding 
the correlates of protection for the major sexually transmitted pathogens, understanding how 
cycle-associated changes in female sex hormones impact on the induction of and 
effectiveness of vaccine-induced immunity, defining the best route(s) of immunisation to 
target the female (and male) reproductive tracts, selection of the best antigen(s) and adjuvant 
combinations to elicit protective immunity and defining who and when to vaccinate. Antigen 
discovery research using animal models has identified potential protective antigens for most 
important STIs and a greater understanding of innate immunity has led to the development of 
many novel adjuvants and adjuvant combinations that are currently in human clinical trials. 
The key to developing vaccines against the major human STIs is the translation of knowledge 
gained from pre-clinical studies in animal models into human clinical trials. The successful 
development of vaccines to target HPV infections and cervical cancer provide an example of 
how this can be achieved and has also increased social acceptance of vaccines for STIs.     
 
 
Key Issues  
 Determining the mechanisms of immune protection against the various sexually 
transmitted pathogens is essential for vaccine development. Cervicovaginal secretions 
contain both IgG and IgA, and both subclasses may impact on protection. For 
example IgA may prevent infection via immune exclusion whilst IgG may provide a 
key link between innate and adaptive immunity by facilitating antibody dependent 
cellular cytotoxicity (ADCC) by FcR+ cells such as NK cells. Interferon gamma 
producing CD4 T cells are essential for protection against intracellular pathogens such 
as Chlamydia, however studies in animal models show that recruitment of memory T 
cells into the FRT only occurs as a result of infection and may not occur in time to 
prevent infection. This may mean that induction of sterilising immunity is not 
possible for some STIs. 
 Is sterilising immunity an essential requirement for all STI vaccines? For infections 
caused by C. trachomatis for example, modelling studies suggest that even partially 
effective vaccines could have a major impact on the incidence of infection at a 
population level, as a result of decreasing the magnitude and duration of infection in 
vaccinated individuals and increasing the critical load required for infection of 
vaccinated individuals. Such outcomes should be effective from a public health 
perspective in reducing the incidence and burden of a disease, however acceptance of 
a vaccine that does not provide sterilising immunity would represent a major 
paradigm shift. 
 What is the best route of immunisation to target immunity to the FRT? Studies in 
animal models suggest that intranasal immunisation, for example, is particularly 
effective at eliciting protective immunity against a number of sexually transmitted 
pathogens. Studies of needle-free mucosal (intranasal, oral, vaginal, transcutaneous) 
vaccination in humans are required to determine if mucosal immunisation elicits 
better protection than current intramuscular injection, as is used to deliver the HPV 
vaccines Gardasil® and Cerverix®.  
 Adjuvants other than those currently approved for human use (Alum, MF59 and 
AS03) are essential for the development of effective vaccines against STIs. These 
must be non-toxic and safe for human use, facilitate mucosal vaccine delivery and 
allow for induction of immune responses tailored to specific pathogens, for example 
induction of mixed Th1/Th2 responses with or without a CD8 CTL response. An 
increased understanding of PAMP/PRR interactions required for activation of innate 
immunity should facilitate the development of new adjuvants and several combination 
adjuvants have shown promise in animal models.   
 Vaccine efficacy may be impacted by hormonal impacts on the immune response 
elicited by vaccines. The data supporting this view comes predominantly from animal 
models and it remains unclear if this will represent an obstacle for development of 
vaccines to target human STIs. It will be essential to determine in humans if hormonal 
status affects either induction of immunity by vaccination or the effectiveness of 
vaccine-induced protection. The success of vaccines targeting HPV infections and 
cervical cancer is encouraging. 
 The ability to implement vaccination programs to the most suitable target age to 
ensure immunity is effectively acquired before risk of exposure has been a potential 
hurdle which was recently overcome in the HPV vaccination program (i.e. 
prepubescent females have recently been targeted for the HPV vaccines; pre-exposure 
immunisation). Furthermore, could the effectiveness of STI vaccines at the population 
level be increased by also vaccinating males? 
 Gender specific vaccination approaches are already being trialled (eg for HSV) and 
this may be necessary to successfully protect both the males and females from 
infection. Could the state of immune privilege that exists in the male reproductive 
tract represent a barrier to induction of protective immunity against STIs in males and 
could immune mechanisms of protection differ between genders?  
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